Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties. Following the initial research phase, Vaccinex may receive certain options
Results from the 165-patient trial demonstrated that nalbuphine ER positively reduced pain intensity in a dose-dependent manner over the 12-hour study period. Positive results were also observed in
The company also announced that the drug has received orphan drug designation from the FDA for the treatment of pancreatic cancer. In the US, 32,000 patients annually are
Under the agreed upon terms Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra’s technologies for inducible siRNA, a unique nano-particle system for delivery of
Specifically, the product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need
The initial license granted to Genentech allows the US biotechnology company to use the GS system only for R&D purposes. However, the agreement does provide options for Genentech
According to the report authors, there is a lack of quantifiable evidence on the costs and benefits of implementing major policies such as reducing waiting times within the
Data from Sangamo’s developmental program has shown that its zinc finger DNA-binding protein (ZFP) can be used to make cells resistant to HIV infection by permanently modifying the
Mammography and physical examination are both used to detect the possibility of breast cancer. A woman receiving an abnormal mammogram or physical examination needs further confirmation to determine
The report investigated the way the agency reviews applications for drugs and biologics that have not previously been FDA-approved. It was commissioned to look at differences in applications
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.